Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

Antidepressant Drugs: Overview

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...

Depressive Disorders: MDD and Dysthymia

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...

Depressive Disorders: Etiology

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...

Anxiolytic Drugs: Overview

Anxiolytic Drugs: Overview

Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction: Ivosidenib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2024

Same author

Pemigatinib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2024

Same author

Ivosidenib: A Review in Advanced Cholangiocarcinoma.

Targeted oncology·2023

Same author

Epcoritamab: First Approval.

Drugs·2023

Same author

Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.

Drugs·2023

Same author

Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.

Drugs·2023

Search research articles

Related Experiment Video

Updated: May 31, 2026

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

Vilazodone: in major depressive disorder.

James E Frampton¹

¹Adis, a Wolters Kluwer Business, Auckland, New Zealand.

|June 25, 2011

Summary

Vilazodone effectively treats major depressive disorder (MDD) by combining SSRI and 5-HT1A partial agonist activities. Clinical trials show significant symptom improvement with good tolerability and minimal sexual side effects.

Area of Science:

Pharmacology
Psychiatry
Clinical Trials

Background:

Major Depressive Disorder (MDD) is a prevalent and debilitating mental health condition.
Existing treatments for MDD have limitations, necessitating novel therapeutic approaches.
Vilazodone represents a novel antidepressant agent with a dual mechanism of action.

Purpose of the Study:

To evaluate the efficacy and tolerability of vilazodone in the short-term and long-term treatment of MDD.
To assess vilazodone's impact on depressive symptoms using validated rating scales.
To investigate the safety profile and side effects associated with vilazodone treatment.

Main Methods:

Two pivotal 8-week, randomized, double-blind, placebo-controlled phase III studies were conducted.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Related Experiment Videos

Last Updated: May 31, 2026

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

A 52-week, non-comparative, phase III study assessed long-term treatment outcomes.

Efficacy was measured using the Montgomery-Åsberg Depression Rating Scale (MADRS) and Hamilton Rating Scale for Depression (HAM-D-17).

Main Results:

Vilazodone demonstrated significant improvements in depressive symptoms compared to placebo in short-term studies.
Efficacy was observed as early as one week of treatment in one study.
Long-term vilazodone treatment was associated with sustained improvement in depressive symptoms.
The most common adverse events were diarrhea and nausea.
Vilazodone exhibited minimal impact on sexual functioning.

Conclusions:

Vilazodone is an effective oral treatment for MDD in adults.
The medication is generally well-tolerated for both short-term and long-term use.
Vilazodone offers a favorable safety profile, including minimal sexual dysfunction, making it a valuable option for MDD management.